JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type

Liu,Jumei; Liang,Li; Li,Dong; Nong,Lin; Zheng,Yalin; Huang,Sixia; Zhang,Bo; Li,Ting

doi:10.3892/or.2019.7112

JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type

Authors:
- Jumei Liu
- Li Liang
- Dong Li
- Lin Nong
- Yalin Zheng
- Sixia Huang
- Bo Zhang
- Ting Li
View Affiliations

Affiliations: Department of Pathology, Peking University First Hospital, Beijing 100034, P.R. China, Department of Pathology, Peking University Health Science Center, Beijing 100191, P.R. China
Published online on: April 12, 2019 https://doi.org/10.3892/or.2019.7112
Pages: 3219-3232
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The inactivation of tumor suppressor gene positive regulatory domain containing I (PRDM1) and activation of signal transducer and activator of transcription 3 (STAT3) have been detected in the majority of extranodal NK/T‑cell lymphoma, nasal type (EN‑NK/T‑NT) cases. In the present study, their association with and effects on the clinicopathologic features of EN‑NK/T‑NT are described. PRDM1 was revealed to be expressed in 19 out of 58 patients (32.8%) with EN‑NK/T‑NT, and phosphorylated STAT3 was overexpressed in 42 out of 58 (72.4%). Oncogenic pathways were investigated by NanoString encounter technology in 5 PRDM1(+) and 5 PRDM1(‑) EN‑NK/T‑NT specimens. Multiple oncogenic pathways involved in cell apoptosis, cellcycle (CC) and angiogenesis were discriminately activated in EN‑NK/T‑NT cases, and in PRDM1(+) cases in particular. The sustained activation of the Janus kinase 3 (JAK)/STAT3 pathway was more pronounced. In addition, missense mutations in the SRC homology 2 domain of STAT3 were detected in 7 out of 37 EN‑NK/T‑NT cases (18.92%), and the acquired mutation was related to the activation of the JAK3/STAT3 pathway. The downregulation of PRDM1 and upregulation of phospho‑STAT3 (Tyr705) were associated with angiocentric infiltration of EN‑NK/T‑NT (P=0.039). Notably, the prognosis of patients in the PRDM1(+)/STAT3 [mutated (mut‑)] group was considerably improved than that of patients in the STAT3(mut+)/PRDM(‑) group (P=0.037). In addition, the inhibition of NK/T cell lymphoma cell lines by Stattic and tofacitinib could suppress cell proliferation by inducing cell apoptosis or arresting the CC. The present results revealed that the JAK3/STAT3 oncogenic pathway and PRDM1 expression could stratify clinicopathologic features of EN‑NK/T‑NT. The inhibition of the JAK3/STAT3 pathway may serve as a treatment option for EN‑NK/T‑NT.

View Figures

View References

1	Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, et al: Nasal-type NK/T cell lymphoma: Clinical features and treatment outcome. Br J Cancer. 92:1226–1230. 2005. View Article : Google Scholar : PubMed/NCBI
2	Tse E and Kwong YL: The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 10:852017. View Article : Google Scholar : PubMed/NCBI
3	Tse E and Kwong YL: How I treat NK/T-cell lymphomas. Blood. 121:4997–5005. 2013. View Article : Google Scholar : PubMed/NCBI
4	Makita S and Tobinai K: Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematol Oncol Clin North Am. 31:239–253. 2017. View Article : Google Scholar : PubMed/NCBI
5	Iqbal J, Kucuk C, Deleeuw RJ, Srivastava G, Tam W, Geng H, Klinkebiel D, Christman JK, Patel K, Cao K, et al: Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 23:1139–1151. 2009. View Article : Google Scholar : PubMed/NCBI
6	Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K, Nakashima Y, Shimizu N, Ko YH, Morishima Y, Ohshima K, et al: Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 118:3195–3204. 2011. View Article : Google Scholar : PubMed/NCBI
7	Küçük C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G, Au WY, McKeithan TW and Chan WC: PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA. 108:20119–20124. 2011. View Article : Google Scholar : PubMed/NCBI
8	Huang Y, de Leval L and Gaulard P: Molecular underpinning of extranodal NK/T-cell lymphoma. Best Pract Res Clin Haematol. 26:57–74. 2013. View Article : Google Scholar : PubMed/NCBI
9	Liang L, Nong L, Zhang S, Zhao J, Ti H, Dong Y, Zhang B and Li T: The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res. 33:72014. View Article : Google Scholar : PubMed/NCBI
10	Liang L, Zhang Z, Wang Y, Nong L, Zheng Y, Qu L, Zhang B and Li T: The genetic deletion of 6q21 and PRDM1 and clinical implications in extranodal NK/T cell lymphoma, nasal type. Biomed Res Int. 2015:4354232015. View Article : Google Scholar : PubMed/NCBI
11	Zhang Z, Liang L, Li D, Nong L, Liu J, Qu L, Zheng Y, Zhang B and Li T: Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: An evidence of predominant role in its downregulation. Hematol Oncol. 35:645–654. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, Kwak SH, Park KS, Yoo HY, Kim WS, et al: Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 6:17764–17776. 2015.PubMed/NCBI
13	Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, et al: Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 223:496–510. 2011. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Shen Y, Wang S, Shen Q and Zhou X: The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 415:117–128. 2018. View Article : Google Scholar : PubMed/NCBI
15	Chen YW, Guo T, Shen L, Wong KY, Tao Q, Choi WW, Au-Yeung RK, Chan YP, Wong ML, Tang JC, et al: Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. Blood. 125:1589–1600. 2015. View Article : Google Scholar : PubMed/NCBI
16	Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, Perrot C, Vieillard V, Dartigues P, Gaulard P, et al: STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia. 23:1667–1678. 2009. View Article : Google Scholar : PubMed/NCBI
17	Küçük C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W, Lack N, Alkan C, Williams JC, Avery KN, et al: Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun. 6:60252015. View Article : Google Scholar : PubMed/NCBI
18	Cazzola M: Introduction to a review series: The 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 127:2361–2364. 2016. View Article : Google Scholar : PubMed/NCBI
19	Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R and Ritz J: Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 24:406–415. 1996.PubMed/NCBI
20	Gong JH, Maki G and Klingemann HG: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 8:652–658. 1994.PubMed/NCBI
21	Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, et al: TCGF (IL-2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol. 134:1623–1630. 1985.PubMed/NCBI
22	Garcia JF, Roncador G, Garcia JF, Sánz AI, Maestre L, Lucas E, Montes-Moreno S, Fernandez Victoria R, Martinez-Torrecuadrara JL, Marafioti T, et al: PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica. 91:467–474. 2006.PubMed/NCBI
23	Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LH, Chadburn A, Tuschl T, Knowles DM and Tam W: MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: A potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 173:242–252. 2008. View Article : Google Scholar : PubMed/NCBI
24	Nie K, Zhang T, Allawi H, Gomez M, Liu Y, Chadburn A, Wang YL, Knowles DM and Tam W: Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: A potential role of the microRNA let-7. Am J Pathol. 177:1470–1479. 2010. View Article : Google Scholar : PubMed/NCBI
25	Yuan J, Zhang F and Niu R: Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep. 5:176632015. View Article : Google Scholar : PubMed/NCBI
26	Wu ZL, Song YQ, Shi YF and Zhu J: High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 4:312014.
27	Khanna P, Chua PJ, Bay BH and Baeg GH: The JAK/STAT signaling cascade in gastric carcinoma (Review). Int J Oncol. 47:1617–1626. 2015. View Article : Google Scholar : PubMed/NCBI
28	Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, Aline-Fardin A, Mercher T, Gaulard P, Nyga R, Jeziorowska D, et al: JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia. 28:338–348. 2014. View Article : Google Scholar : PubMed/NCBI
29	Nairismägi M, Gerritsen ME, Li ZM, Wijaya GC, Chia BKH, Laurensia Y, Lim JQ, Yeoh KW, Yao XS, Pang WL, et al: Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia. 32:1147–1156. 2018. View Article : Google Scholar : PubMed/NCBI
30	Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, Keam B, Park HH, Kim DW, Kim CW and Heo DS: Novel JAK3-activating mutations in extranodal NK/T-cell lymphoma, nasal type. Am J Pathol. 187:980–986. 2017. View Article : Google Scholar : PubMed/NCBI
31	Xu Y, Shi Y, Yuan Q, Liu X, Yan B, Chen L, Tao Y and Cao Y: Epstein-Barr virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J Exp Clin Cancer Res. 32:902013. View Article : Google Scholar : PubMed/NCBI
32	Dobashi A, Tsuyama N, Asaka R, Togashi Y, Ueda K, Sakata S, Baba S, Sakamoto K, Hatake K and Takeuchi K: Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type. Genes Chromosomes Cancer. 55:460–471. 2016. View Article : Google Scholar : PubMed/NCBI
33	Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, et al: Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 47:1061–1066. 2015. View Article : Google Scholar : PubMed/NCBI
34	Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, et al: Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2:591–597. 2012. View Article : Google Scholar : PubMed/NCBI
35	Kimura H, Karube K, Ito Y, Hirano K, Suzuki M, Iwata S and Seto M: Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan. Leuk Lymphoma. 55:962–963. 2014. View Article : Google Scholar : PubMed/NCBI
36	Ryu JG, Lee J, Kim EK, Seo HB, Park JS, Lee SY, Moon YM, Yoo SH, Park YW, Park SH, et al: Treatment of IL-21R-Fc control autoimmune arthritis via suppression of STAT3 signal pathway mediated regulation of the Th17/Treg balance and plasma B cells. Immunol Lett. 163:143–150. 2015. View Article : Google Scholar : PubMed/NCBI
37	Barnes NA, Stephenson S, Cocco M, Tooze RM and Doody GM: BLIMP-1 and STAT3 counterregulate microRNA-21 during plasma cell differentiation. J Immunol. 189:253–260. 2012. View Article : Google Scholar : PubMed/NCBI
38	Heidelberger S, Zinzalla G, Antonow D, Essex S, Basu BP, Palmer J, Husby J, Jackson PJ, Rahman KM, Wilderspin AF, et al: Investigation of the protein alkylation sites of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorg Med Chem Lett. 23:4719–4722. 2013. View Article : Google Scholar : PubMed/NCBI
39	Quintás-Cardama A and Verstovsek S: Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and resistance. Clin Cancer Res. 19:1933–1940. 2013. View Article : Google Scholar : PubMed/NCBI
40	Banerjee S, Biehl A, Gadina M, Hasni S and Schwartz DM: JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs. 77:521–546. 2017. View Article : Google Scholar : PubMed/NCBI
41	Ando S, Kawada JI, Watanabe T, Suzuki M, Sato Y, Torii Y, Asai M, Goshima F, Murata T, Shimizu N, et al: Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Oncotarget. 7:76793–76805. 2016. View Article : Google Scholar : PubMed/NCBI
42	Vainchenker W, Leroy E, Gilles L, Marty C, Plo I and Constantinescu SN: JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 7:822018. View Article : Google Scholar : PubMed/NCBI